1. First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter. (June 2019) Authors: Belohlavkova, Petra; Steinerova, Katerina; Karas, Michal; Skoumalova, Iva; Rohon, Peter; Indrak, Karel; Voglova, Jaroslava; Vrbacky, Filip; Cmunt, Eduard; Necasova, Tereza; Kristkova, Zlatuse; Trneny, Marek; Zak, Pavel; Papajik, Tomas; Faber, Edgar Journal: Leukemia research Issue: Volume 81(2019) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Imatinib and pegylated IFN‐α2b discontinuation in first‐line chronic myeloid leukemia patients following a major molecular response. (28th January 2014) Authors: Koskenvesa, Perttu; Kreutzman, Anna; Rohon, Peter; Pihlman, Markus; Vakkila, Emmi; Räsänen, Anu; Vapaatalo, Mirja; Remes, Kari; Lundán, Tuija; Hjorth‐Hansen, Henrik; Vakkila, Jukka; Simonsson, Bengt; Mustjoki, Satu; Porkka, Kimmo Journal: European journal of haematology Issue: Volume 92:Number 5(2014:May) Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports. (28th May 2012) Authors: Rohon, Peter; Vondrakova, Jana; Jonasova, Anna; Holzerova, Milena; Jarosova, Marie; Indrak, Karel Other Names: Bissé E. Academic Editor.; Khair K. Academic Editor. Journal: Case reports in hematology Issue: Volume 2012(2012) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗